These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 22460556)

  • 21. Both rare and common variants in PCSK9 influence plasma low-density lipoprotein cholesterol level in American Indians.
    Tsai CW; North KE; Tin A; Haack K; Franceschini N; Saroja Voruganti V; Laston S; Zhang Y; Best LG; MacCluer JW; Beaty TH; Navas-Acien A; Kao WH; Howard BV
    J Clin Endocrinol Metab; 2015 Feb; 100(2):E345-9. PubMed ID: 25412415
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relation of circulating PCSK9 concentration to fibrinogen in patients with stable coronary artery disease.
    Zhang Y; Zhu CG; Xu RX; Li S; Guo YL; Sun J; Li JJ
    J Clin Lipidol; 2014; 8(5):494-500. PubMed ID: 25234562
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of lipoprotein apheresis on PCSK9 levels.
    Julius U; Milton M; Stoellner D; Rader D; Gordon B; Polk D; Waldmann E; Parhofer KG; Moriarty PM
    Atheroscler Suppl; 2015 May; 18():180-6. PubMed ID: 25936324
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type 2 diabetic patients.
    Nekaies Y; Baudin B; Kelbousi S; Sakly M; Attia N
    J Diabetes Complications; 2015; 29(8):1165-70. PubMed ID: 26412029
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of insulin on circulating PCSK9 in postmenopausal obese women.
    Awan Z; Dubuc G; Faraj M; Dufour R; Seidah NG; Davignon J; Rabasa-Lhoret R; Baass A
    Clin Biochem; 2014 Aug; 47(12):1033-9. PubMed ID: 24721682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans.
    Persson L; Cao G; Ståhle L; Sjöberg BG; Troutt JS; Konrad RJ; Gälman C; Wallén H; Eriksson M; Hafström I; Lind S; Dahlin M; Amark P; Angelin B; Rudling M
    Arterioscler Thromb Vasc Biol; 2010 Dec; 30(12):2666-72. PubMed ID: 20884874
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue.
    Roubtsova A; Munkonda MN; Awan Z; Marcinkiewicz J; Chamberland A; Lazure C; Cianflone K; Seidah NG; Prat A
    Arterioscler Thromb Vasc Biol; 2011 Apr; 31(4):785-91. PubMed ID: 21273557
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relation of resistin to proprotein convertase subtilisin-kexin type 9 levels in coronary artery disease patients with different nutritional status.
    Li S; Xu RX; Zhang Y; Guo YL; Zhu CG; Liu G; Dong Q; Li JJ
    J Endocrinol Invest; 2015 Dec; 38(12):1291-9. PubMed ID: 26003826
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Removal of plasma mature and furin-cleaved proprotein convertase subtilisin/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9.
    Hori M; Ishihara M; Yuasa Y; Makino H; Yanagi K; Tamanaha T; Kishimoto I; Kujiraoka T; Hattori H; Harada-Shiba M
    J Clin Endocrinol Metab; 2015 Jan; 100(1):E41-9. PubMed ID: 25313916
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Leptin Replacement on PCSK9 in ob/ob Mice and Female Lipodystrophic Patients.
    Levenson AE; Haas ME; Miao J; Brown RJ; de Ferranti SD; Muniyappa R; Biddinger SB
    Endocrinology; 2016 Apr; 157(4):1421-9. PubMed ID: 26824363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PCSK9 and lipid lowering drugs.
    Guo YL; Zhang W; Li JJ
    Clin Chim Acta; 2014 Nov; 437():66-71. PubMed ID: 25036764
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regional distribution and metabolic effect of PCSK9 insLEU and R46L gene mutations and apoE genotype.
    Awan Z; Delvin EE; Levy E; Genest J; Davignon J; Seidah NG; Baass A
    Can J Cardiol; 2013 Aug; 29(8):927-33. PubMed ID: 23743349
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The associations between proprotein convertase subtilisin/kexin type 9 E670G polymorphism and the risk of coronary artery disease and serum lipid levels: a meta-analysis.
    Cai G; Zhang B; Shi G; Weng W; Ma C; Song Y; Zhang J
    Lipids Health Dis; 2015 Nov; 14():149. PubMed ID: 26576960
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship of proprotein convertase subtilisin-kexin type 9 levels with resistin in lean and obese subjects.
    Kwakernaak AJ; Lambert G; Dullaart RP
    Clin Biochem; 2012 Nov; 45(16-17):1522-4. PubMed ID: 22809551
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of estrogen on serum level and hepatocyte expression of PCSK9.
    Guo W; Fu J; Chen X; Gao B; Fu Z; Fan H; Cui Q; Zhu X; Zhao Y; Yang T; Fan D; Zhou H
    Metabolism; 2015 Apr; 64(4):554-60. PubMed ID: 25665485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: results from a crossover study.
    Noguchi T; Kobayashi J; Yagi K; Nohara A; Yamaaki N; Sugihara M; Ito N; Oka R; Kawashiri MA; Tada H; Takata M; Inazu A; Yamagishi M; Mabuchi H
    Atherosclerosis; 2011 Jul; 217(1):165-70. PubMed ID: 21411093
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial.
    Fitzgerald K; Frank-Kamenetsky M; Shulga-Morskaya S; Liebow A; Bettencourt BR; Sutherland JE; Hutabarat RM; Clausen VA; Karsten V; Cehelsky J; Nochur SV; Kotelianski V; Horton J; Mant T; Chiesa J; Ritter J; Munisamy M; Vaishnaw AK; Gollob JA; Simon A
    Lancet; 2014 Jan; 383(9911):60-68. PubMed ID: 24094767
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis.
    Chen SN; Ballantyne CM; Gotto AM; Tan Y; Willerson JT; Marian AJ
    J Am Coll Cardiol; 2005 May; 45(10):1611-9. PubMed ID: 15893176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of plasma small dense LDL cholesterol with PCSK9 levels in patients with angiographically proven coronary artery disease.
    Zhang Y; Xu RX; Li S; Zhu CG; Guo YL; Sun J; Li JJ
    Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):426-33. PubMed ID: 25770756
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relation of plasma PCSK9 levels to lipoprotein subfractions in patients with stable coronary artery disease.
    Xu RX; Li S; Zhang Y; Li XL; Guo YL; Zhu CG; Li JJ
    Lipids Health Dis; 2014 Dec; 13():188. PubMed ID: 25496400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.